Editas Medicine (EDIT) Competitors

$5.62
-0.27 (-4.58%)
(As of 05/17/2024 08:53 PM ET)

EDIT vs. VYGR, FATE, TSHA, LXEO, OCGN, TCRX, ALLO, ALEC, CCCC, and REPL

Should you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Taysha Gene Therapies (TSHA), Lexeo Therapeutics (LXEO), Ocugen (OCGN), TScan Therapeutics (TCRX), Allogene Therapeutics (ALLO), Alector (ALEC), C4 Therapeutics (CCCC), and Replimune Group (REPL). These companies are all part of the "biological products, except diagnostic" industry.

Editas Medicine vs.

Editas Medicine (NASDAQ:EDIT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Voyager Therapeutics had 8 more articles in the media than Editas Medicine. MarketBeat recorded 26 mentions for Voyager Therapeutics and 18 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.81 beat Voyager Therapeutics' score of 0.40 indicating that Editas Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Editas Medicine
6 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Voyager Therapeutics
4 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Editas Medicine presently has a consensus target price of $13.90, indicating a potential upside of 147.33%. Voyager Therapeutics has a consensus target price of $18.00, indicating a potential upside of 113.52%. Given Editas Medicine's higher possible upside, analysts clearly believe Editas Medicine is more favorable than Voyager Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine
0 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Voyager Therapeutics
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 4.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Voyager Therapeutics received 77 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 67.32% of users gave Voyager Therapeutics an outperform vote while only 53.83% of users gave Editas Medicine an outperform vote.

CompanyUnderperformOutperform
Editas MedicineOutperform Votes
302
53.83%
Underperform Votes
259
46.17%
Voyager TherapeuticsOutperform Votes
379
67.32%
Underperform Votes
184
32.68%

Voyager Therapeutics has higher revenue and earnings than Editas Medicine. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$78.12M5.92-$153.22M-$2.10-2.68
Voyager Therapeutics$119.04M3.85$132.33M-$0.05-168.60

Voyager Therapeutics has a net margin of -2.56% compared to Editas Medicine's net margin of -239.36%. Voyager Therapeutics' return on equity of -1.28% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Editas Medicine-239.36% -47.34% -33.46%
Voyager Therapeutics -2.56%-1.28%-0.85%

Summary

Voyager Therapeutics beats Editas Medicine on 11 of the 17 factors compared between the two stocks.

Get Editas Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDIT vs. The Competition

MetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$462.18M$2.95B$5.37B$7.98B
Dividend YieldN/A2.18%44.70%3.91%
P/E Ratio-2.6830.43139.1318.77
Price / Sales5.92324.572,368.3485.85
Price / CashN/A163.2336.9831.98
Price / Book1.577.135.514.64
Net Income-$153.22M-$43.11M$106.10M$217.28M
7 Day Performance5.64%4.10%1.42%2.90%
1 Month Performance2.37%10.40%4.97%6.66%
1 Year Performance-39.70%6.94%7.98%9.89%

Editas Medicine Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYGR
Voyager Therapeutics
3.827 of 5 stars
$8.48
flat
$17.67
+108.3%
-36.0%$461.21M$250.01M2.74162Analyst Revision
FATE
Fate Therapeutics
4.1576 of 5 stars
$4.22
+1.7%
$6.75
+60.0%
-21.7%$480.36M$63.53M-2.20181Analyst Revision
TSHA
Taysha Gene Therapies
2.1048 of 5 stars
$2.57
+7.1%
$6.88
+167.5%
+317.8%$480.64M$15.45M-3.8452Earnings Report
Analyst Revision
LXEO
Lexeo Therapeutics
2.6924 of 5 stars
$13.97
+3.0%
$20.80
+48.9%
N/A$446.73M$650,000.00-0.6358
OCGN
Ocugen
0.7554 of 5 stars
$1.70
-6.1%
$4.67
+174.5%
+183.5%$437.46M$6.04M-6.3065Earnings Report
Analyst Revision
Gap Down
TCRX
TScan Therapeutics
2.1973 of 5 stars
$8.99
+12.2%
$12.00
+33.5%
+180.6%$430.44M$21.05M-4.76154
ALLO
Allogene Therapeutics
2.384 of 5 stars
$2.96
+2.1%
$13.50
+356.1%
-54.4%$505.33M$90,000.00-1.42232Earnings Report
Analyst Revision
High Trading Volume
ALEC
Alector
3.3456 of 5 stars
$5.33
-1.1%
$14.00
+162.7%
-28.3%$513.76M$97.06M-3.86244Gap Up
CCCC
C4 Therapeutics
0.9395 of 5 stars
$6.00
-2.8%
$10.11
+68.5%
+73.7%$412.86M$20.76M-2.53145
REPL
Replimune Group
4.3987 of 5 stars
$6.71
+1.8%
$37.67
+461.4%
-67.1%$411.91MN/A-2.12284Analyst Revision
News Coverage

Related Companies and Tools

This page (NASDAQ:EDIT) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners